AMO Pharma

     Drug: AMO-02 (tideglusib)

     Approach: Small Molecule Inhibitor of Glycogen Kinase 3 Beta

     Status: Completed Phase 2 Study. Phase 2/3 Study Listed on ClinicalTrials.gov but is not enrolling patients at this time.

     Company's Description of Drug

     Presentation at 2018 MDF Conference

     October 3, 2018 Press Release: AMO Therapeutics Announces Presentation of Concordant Analysis of Results of Phase 2 Study of AMO-02 in treatment of myotonic dystrophy

     June 13, 2019 Press Release: Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting